Poor
Not Aligned
Patient Risk:
High
Summary
Many effectiveness/mechanism statements broadly align with the label excerpts, but the response includes multiple incorrect safety/labeling assertions regarding contraindications (label states none). Several other claims are unsupported or overgeneralized.
Category Scores
Accurate Statements
Humira is used to treat rheumatoid arthritis.
1.1 Rheumatoid Arthritis
Humira is used to treat plaque psoriasis.
1.7 Plaque Psoriasis
Humira is used to treat Crohn's disease.
1.5 Crohn’s Disease
Humira is used to treat ulcerative colitis.
1.6 Ulcerative Colitis
Humira belongs to the class of tumor necrosis factor (TNF) inhibitors.
12.1 Mechanism of Action (TNF-alpha binding/blocking); HUMIRA referred to as TNF blocker in 5 WARNINGS AND PRECAUTIONS
Humira works by blocking the action of TNF.
12.1 Mechanism of Action (blocks interaction with TNF receptors)
Humira can cause injection site reactions, including redness, swelling, and itching.
6.1 Clinical Trials Experience (injection site reactions including erythema and/or itching and pain or swelling)
Humira can cause headaches.
6.1 Clinical Trials Experience (Headache listed among adverse reactions)
Humira can reactivate latent tuberculosis.
5.1 Serious Infections (reactivation of tuberculosis and new onset tuberculosis reported)
Humira can worsen hepatitis B.
5.4 Hepatitis B Virus Reactivation (increased risk of HBV reactivation; some reports fatal)
Unsupported Statements
Humira is a biologic medication.
The provided label excerpts do not explicitly state 'biologic medication'.
Humira can cause fatigue.
The provided label excerpts do not mention fatigue as an adverse reaction.
Humira's patent is set to expire in 2023.
Not supported by any of the provided label excerpts.
By blocking TNF, Humira reduces inflammation and swelling associated with these conditions.
TNF mechanism is supported, but the provided excerpts do not explicitly substantiate 'swelling' in this generalized phrasing.
Humira reduces the symptoms of inflammatory conditions.
Label supports reducing signs and symptoms for specific indicated diseases, but the provided excerpts do not support this generalized wording across 'inflammatory conditions'.
Humira improves functionality by reducing inflammation, enabling patients to perform daily activities with greater ease.
Improving physical function/daily activity is supported, but the provided excerpts do not explicitly support the causal phrasing 'by reducing inflammation'.
Studies have shown that Humira can induce remission in patients with rheumatoid arthritis and other inflammatory conditions.
Remission induction is described for Crohn’s and ulcerative colitis in the provided excerpts; the RA excerpt provided describes clinical response/major clinical response rather than 'induce remission'.
Humira has been shown to be effective in the long-term management of inflammatory conditions.
Longer duration/maintenance is described for specific diseases in the provided excerpts, but not as a generalized statement across 'inflammatory conditions'.
Contradictions
High
AI Statement
Humira is contraindicated in patients with active tuberculosis.
Label Reference
4 CONTRAINDICATIONS (None.); 5.1 Serious Infections addresses active infection and tuberculosis risk/monitoring rather than contraindication status.
High
AI Statement
Humira is contraindicated in patients with moderate to severe hepatitis B.
Label Reference
4 CONTRAINDICATIONS (None.); 5.4 Hepatitis B Virus Reactivation provides risk/monitoring and management steps rather than a contraindication.
Important Omissions
When discussing tuberculosis and hepatitis B safety, the label excerpts include specific recommended actions (e.g., evaluate/test for latent TB prior to initiation and periodically; monitor for infection; exercise caution and closely monitor HBV carriers; stop HUMIRA and initiate antivirals if HBV reactivation occurs).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response incorrectly states contraindications for active tuberculosis and moderate to severe hepatitis B, while the provided label excerpt states 'None' under contraindications. This could lead to improper exclusion or misinterpretation of labeled precautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Incorrect contraindication claims: label contraindications are 'None' while the response adds contraindications for active tuberculosis and moderate/severe hepatitis B.
Suggested Improvement
Remove contraindication statements and instead reflect the label’s warnings/precautions (TB risk/monitoring and HBV reactivation risk/monitoring and management). Limit generalized statements (e.g., 'inflammatory conditions', 'long-term management') to what is explicitly supported in the provided label excerpts.